MAPT and Alzheimer disease: We demonstrate that by normalizing tau368 to t-tau, there is a stronger relationship with uptake of a second-generation tau PET tracer in individuals with symptomatic AD as compared to using either of the biomarkers in isolation, especially in limbic and isocortical brain regions.